Britain and America have announced a important trade agreement that will maintain zero tariffs on British pharmaceutical products going into the American market.
Agreement Details of the Pact
As part of the deal, the UK has committed to raise expenditure on drugs through the NHS. This move secures that import taxes on these key exports will be held at zero for a timeframe of 36 months.
This deal comes after earlier statements to hike import taxes on branded drug products, with figures mentioned reaching 100%.
"This agreement between the UK strengthens the worldwide climate for innovative medicines and establishes long-overdue fairness to American-British medicine commerce," a release noted.
Economic Significance
Pharmaceuticals constitute one of the the United Kingdom's largest export categories to the United States, which is by far the biggest destination for large companies like GSK and AstraZeneca.
Export figures reveal that in the year leading up to the third quarter, the UK sold drugs worth billions to the US. This amount made up 17.4% of all goods exports in that period.
"This deal secures employment, boosts capital expenditure and paves the way for the UK to become a global hub for medical research," a government official stated.
Detailed UK Commitments
The deal entails several specific changes from the UK:
- Revised Affordability Limit: The UK will raise the price threshold at which it deems new therapies to be too expensive by a quarter.
- Increased NHS Spending: There is a target to increase total public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6% over the next decade.
- Payback Limit: The sum drug companies must return to the NHS to stay within budget will be restricted at fifteen percent. Previously, rebates exceeded twenty percent.
Industry Background
The deal follows a long-running dispute between the drug companies and the UK government over drug pricing and NHS adoption.
These tensions were intensified by assertions that US patients were charged a premium for the equivalent treatments than consumers in the other developed nations.
Over the last 18 months, several significant drug company projects in the UK have been delayed or scrapped, while multi-billion-dollar funding commitments have been directed toward US facilities.
One official stated that the NHS must invest a greater share on drugs, noting that its spending on drugs had shrunk as a share of its overall budget over the past decade.
